PE20161442A1 - Proteinas quimericas tipo fosfatasa alcalina - Google Patents

Proteinas quimericas tipo fosfatasa alcalina

Info

Publication number: PE20161442A1
Authority: PE; Peru
Prior art keywords: amino acids; sequence; seq; sequence identity; chemerical
Prior art date: 2014-01-24

Application number

PE2016001271A

Other languages

English (en)

Spanish (es)

Inventor

Jose Luis Millan

Willem Raaben

Elsas Andrea Van

Luigi Johannes Cornelius Jonk

Den Berg Erik Jan Van

Original Assignee

Am-Pharma B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-24

Filing date

2015-01-26

Publication date

2017-01-12

2015-01-26 Application filed by Am-Pharma B V filed Critical Am-Pharma B V

2017-01-12 Publication of PE20161442A1 publication Critical patent/PE20161442A1/es

Links

102000004169 proteins and genes Human genes 0.000 title abstract 4
108090000623 proteins and genes Proteins 0.000 title abstract 4
102000002260 Alkaline Phosphatase Human genes 0.000 title 1
108020004774 Alkaline Phosphatase Proteins 0.000 title 1
150000001413 amino acids Chemical class 0.000 abstract 8
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 2
206010049933 Hypophosphatasia Diseases 0.000 abstract 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)

PE2016001271A 2014-01-24 2015-01-26 Proteinas quimericas tipo fosfatasa alcalina PE20161442A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14152526		2014-01-24
EP14188158		2014-10-08

Publications (1)

Publication Number	Publication Date
PE20161442A1 true PE20161442A1 (es)	2017-01-12

Family

ID=52464544

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2016001271A PE20161442A1 (es)	2014-01-24	2015-01-26	Proteinas quimericas tipo fosfatasa alcalina

Country Status (22)

Country	Link
US (4)	US9926544B2 (ru)
EP (2)	EP3097189B1 (ru)
JP (3)	JP6940949B2 (ru)
KR (1)	KR102166110B1 (ru)
CN (2)	CN111778228A (ru)
AU (1)	AU2015209783B2 (ru)
BR (1)	BR112016017041B1 (ru)
CA (1)	CA2937328C (ru)
DK (1)	DK3097189T3 (ru)
ES (1)	ES2684639T3 (ru)
HU (1)	HUE039784T2 (ru)
IL (1)	IL246898B (ru)
MX (1)	MX369041B (ru)
PE (1)	PE20161442A1 (ru)
PH (1)	PH12016501441A1 (ru)
PL (1)	PL3097189T3 (ru)
RU (1)	RU2683635C2 (ru)
SA (1)	SA516371532B1 (ru)
SG (1)	SG11201606060WA (ru)
SI (1)	SI3097189T1 (ru)
WO (1)	WO2015112017A1 (ru)
ZA (1)	ZA201605028B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111778228A (zh)	2014-01-24	2020-10-16	安-法玛公司	嵌合型碱性磷酸酶样蛋白
US10822596B2 (en)	2014-07-11	2020-11-03	Alexion Pharmaceuticals, Inc.	Compositions and methods for treating craniosynostosis
JP6787894B2 (ja)	2014-12-05	2020-11-18	アレクシオンファーマシューティカルズ，インコーポレイテッド	組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en)	2015-01-28	2016-08-04	Alexion Pharmaceuticals, Inc.	Methods of treating a subject with an alkaline phosphatase deficiency
CN108350440A (zh)	2015-08-17	2018-07-31	阿雷克森制药公司	碱性磷酸酯的制造
WO2017074466A1 (en)	2015-10-30	2017-05-04	Alexion Pharmaceuticals, Inc.	Methods for treating craniosynostosis in a patient
US11065306B2 (en)	2016-03-08	2021-07-20	Alexion Pharmaceuticals, Inc.	Methods for treating hypophosphatasia in children
MX2018011833A (es)	2016-04-01	2019-02-13	Alexion Pharma Inc	Tratamiento para la debilidad muscular con fosfatasas alcalinas.
WO2017214130A1 (en)	2016-06-06	2017-12-14	Alexion Pharmaceuticals, Inc.	Metal impact on manufacturing of alkaline phosphatases
EP3345614A1 (en) *	2017-01-05	2018-07-11	Amrif B.V.	Composition comprising alkaline phosphatase for use in the treatment of arthritides
CA3057502A1 (en)	2017-03-31	2018-10-04	Alexion Pharmaceuticals, Inc.	Methods for treating hypophosphatasia (hpp) in adults and adolescents
WO2019139891A1 (en)	2018-01-09	2019-07-18	Synthetic Biologics, Inc.	Alkaline phosphatase agents for treatment of neurodevelopmental disorders
PL3762018T3 (pl)	2018-03-08	2024-06-17	Am-Pharma B.V.	Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą
CA3094173A1 (en)	2018-03-20	2019-09-26	Synthetic Biologics, Inc.	Intestinal alkaline phosphatase formulations
EP4275761A3 (en)	2018-03-20	2024-02-28	Theriva Biologics, Inc.	Alkaline phosphatase agents for treatment of radiation disorders
JP2021519590A (ja)	2018-03-30	2021-08-12	アレクシオンファーマシューティカルズ，インコーポレイテッド	糖タンパク質の製造
CN110499284A (zh) *	2018-05-17	2019-11-26	西安组织工程与再生医学研究所	Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
CN111110835A (zh) *	2020-01-22	2020-05-08	李鑫荣	一种肠碱性磷酸酶的新应用及其制剂的细胞活性检测方法
US20240009280A1 (en)	2020-09-09	2024-01-11	Am-Pharma B.V.	Recombinant alkaline phosphatase for use in treating acute respiratory distress syndrome

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8328918D0 (en)	1983-10-28	1983-11-30	Unilever Plc	Alkaline phosphatase
ATE157702T1 (de)	1990-02-07	1997-09-15	Abbott Lab	Alkalische phosphatase mit verbesserter spezifischer aktivität zur verwendung in indikatorreagenzien
DE69323131T2 (de)	1992-03-10	1999-09-16	La Jolla Cancer Research Foundation, La Jolla	Rekombinierte alkalische phosphatase aus kälberdarm
JPH06284885A (ja) *	1993-04-02	1994-10-11	Tosoh Corp	組換えヒト小腸アルカリフォスファタ−ゼ
WO1994027603A1 (en)	1993-06-01	1994-12-08	Cortex Pharmaceuticals, Inc.	Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
WO1995005455A1 (en)	1993-08-13	1995-02-23	Rijksuniversiteit Te Groningen	Pharmaceutical composition comprising phosphatase or a derivative thereof
JPH09509141A (ja)	1993-11-15	1997-09-16	セルトリックスファーマシューティカルズ，インコーポレイテッド	Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
CN1192700A (zh)	1995-06-06	1998-09-09	基因科学再生实验室有限公司	改性成骨材料
FR2736065B1 (fr)	1995-06-29	1997-09-19	Commissariat Energie Atomique	Phosphatases alcalines bacteriennes modifiees et leurs applications.
JP3488327B2 (ja)	1995-12-21	2004-01-19	よつ葉乳業株式会社	牛乳脂肪球膜含有画分の製造法
US20020114802A1 (en)	1998-02-10	2002-08-22	Tjellstrom Bo Arthur Einar	Oral immunoglobulin treatment for inflammatory bowel disease
DE19819962A1 (de)	1998-05-05	1999-11-11	Roche Diagnostics Gmbh	Hochaktive alkalische Phosphatase
JP2002533679A (ja)	1998-12-21	2002-10-08	フアーマアウエア・アイピー・ベー・ブイ	アルカリホスファターゼのｌｐｓ−結合部分を使用する敗血症の診断
JP2000350596A (ja)	1999-06-11	2000-12-19	Toyobo Co Ltd	分泌性アルカリフォスファターゼの選択的活性測定方法
IL141120A0 (en)	2000-01-31	2002-02-10	Pfizer Prod Inc	Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
AU2001272761A1 (en)	2000-07-19	2002-01-30	Mitsubishi Pharma Corporation	Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
DE10101793A1 (de)	2001-01-17	2002-08-01	Manfred Nilius	Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
CA2434362A1 (en)	2001-01-20	2002-07-25	Cardion Ag	Pluripotent adult stem cells derived from regenerative tissue
WO2002098433A1 (fr)	2001-06-01	2002-12-12	Ajinomoto Co., Inc.	Medicaments pour les maladies intestinales
US7157260B2 (en)	2001-07-26	2007-01-02	Japan Science & Technology Agency	Nicotianamine synthase and gene encoding the same
JP4169966B2 (ja)	2001-11-14	2008-10-22	株式会社ヤクルト本社	炎症性腸疾患予防治療剤
CN1425766A (zh)	2001-12-19	2003-06-25	复旦大学	一种多肽——人含碱性磷酸酶活性位点的蛋白－9.24和编码这种多肽的多核苷酸
WO2004044178A2 (en) *	2002-11-13	2004-05-27	Genentech, Inc.	Methods and compositions for diagnosing dysplasia
US7048914B2 (en)	2002-12-12	2006-05-23	Zoltan Laboratories	Placental alkaline phosphatase to control diabetes
WO2004056987A1 (en) *	2002-12-23	2004-07-08	Rijksuniversiteit Groningen	Modulation of the thioredoxin pathway
WO2004083432A1 (en)	2003-03-21	2004-09-30	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
JP4305071B2 (ja)	2003-06-30	2009-07-29	株式会社ニコン	信号補正方法
JP2005065564A (ja)	2003-08-22	2005-03-17	Hiroshi Ueda	センサー蛋白質
US7157261B2 (en)	2003-10-27	2007-01-02	Canji, Inc.	Rat secreted embryonic alkaline phosphatase
US20110142817A1 (en)	2004-02-04	2011-06-16	Pharmaaware Sepsis B.V.	Means and method for treating and/or preventing necrotizing enterocolitis
ES2624905T3 (es)	2004-02-04	2017-07-18	Am-Pharma B.V.	Uso de fosfatasa alcalina para la desintoxicación de LPS
US8119385B2 (en)	2005-03-04	2012-02-21	Bp Corporation North America Inc.	Nucleic acids and proteins and methods for making and using them
US20070059300A1 (en)	2005-09-12	2007-03-15	Zoltan Laboratories Llc	Compounds and compositions to control abnormal cell growth
WO2007075199A1 (en)	2005-12-28	2007-07-05	Zoltan Laboratories Llc	Use of alkaline phosphatase to maintain healthy tissue mass in mammals
RU2006103770A (ru) *	2006-02-08	2007-08-20	Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) (Ru)	Высокоактивная бактериальная щелочная фосфатаза и фрагмент днк, кодирующий щелочную фосфатазу
US20070280922A1 (en)	2006-06-06	2007-12-06	Zoltan Kiss Consulting	Combinations of human proteins to enhance viability of stem cells and progenitor cells
US7718170B2 (en)	2006-08-21	2010-05-18	Essential Skincare, Llc	Alkaline phosphatase compositions to reduce skin cancer
EP1952823A1 (en)	2007-01-30	2008-08-06	AM-Pharma B.V.	The use of alkaline phosphatase in the treatment of reduced renal function
WO2008104199A1 (en)	2007-03-01	2008-09-04	Gelato Corporation N.V.	Use of ecto-phosphatases for the treatment of (acute) myocardial infarction
EP1985697A1 (en) *	2007-04-27	2008-10-29	AM-Pharma B.V.	Modified phosphatases
BR122019000505B1 (pt) *	2007-05-11	2022-01-18	Alexion Pharmaceuticals, Inc	Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso
EP2030980A1 (en)	2007-08-28	2009-03-04	AM-Pharma B.V.	Mutants of lactoferrin
CA2716400C (en)	2008-02-29	2017-05-09	Alloksys Life Sciences B.V.	Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
JP2011521916A (ja)	2008-05-19	2011-07-28	バーナムインスティテュートフォーメディカルリサーチ	腸アルカリホスファターゼモジュレーターおよびそれの使用
EP2334306B1 (en)	2008-08-29	2014-04-02	The General Hospital Corporation	Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
CA2797865A1 (en) *	2010-04-30	2011-11-03	Alexion Pharma International Sarl	Methods, compositions, and kits for the treatment of matrix mineralization disorders
HUE052383T2 (hu) *	2011-06-08	2021-04-28	Am Pharma Bv	Az alkalikus foszfatáz alkalmazása a vesemûködés megõrzésére
US10570380B2 (en)	2014-01-24	2020-02-25	Am-Pharma B.V.	Downstream processing of an alkaline phosphatase
CN111778228A (zh)	2014-01-24	2020-10-16	安-法玛公司	嵌合型碱性磷酸酶样蛋白

2015
- 2015-01-26 CN CN202010673719.7A patent/CN111778228A/zh active Pending
- 2015-01-26 HU HUE15703642A patent/HUE039784T2/hu unknown
- 2015-01-26 ES ES15703642.7T patent/ES2684639T3/es active Active
- 2015-01-26 EP EP15703642.7A patent/EP3097189B1/en active Active
- 2015-01-26 SI SI201530345T patent/SI3097189T1/sl unknown
- 2015-01-26 AU AU2015209783A patent/AU2015209783B2/en active Active
- 2015-01-26 DK DK15703642.7T patent/DK3097189T3/en active
- 2015-01-26 MX MX2016009625A patent/MX369041B/es active IP Right Grant
- 2015-01-26 CA CA2937328A patent/CA2937328C/en active Active
- 2015-01-26 EP EP18174759.3A patent/EP3425048A1/en not_active Withdrawn
- 2015-01-26 WO PCT/NL2015/050048 patent/WO2015112017A1/en active Application Filing
- 2015-01-26 BR BR112016017041-5A patent/BR112016017041B1/pt active IP Right Grant
- 2015-01-26 SG SG11201606060WA patent/SG11201606060WA/en unknown
- 2015-01-26 KR KR1020167022726A patent/KR102166110B1/ko active IP Right Grant
- 2015-01-26 PE PE2016001271A patent/PE20161442A1/es unknown
- 2015-01-26 JP JP2016548124A patent/JP6940949B2/ja active Active
- 2015-01-26 RU RU2016131879A patent/RU2683635C2/ru active
- 2015-01-26 CN CN201580016357.1A patent/CN106164262B/zh active Active
- 2015-01-26 PL PL15703642T patent/PL3097189T3/pl unknown
- 2015-01-26 US US15/113,696 patent/US9926544B2/en active Active
2016
- 2016-07-19 ZA ZA2016/05028A patent/ZA201605028B/en unknown
- 2016-07-20 PH PH12016501441A patent/PH12016501441A1/en unknown
- 2016-07-21 SA SA516371532A patent/SA516371532B1/ar unknown
- 2016-07-21 IL IL246898A patent/IL246898B/en active IP Right Grant
2018
- 2018-02-07 US US15/891,208 patent/US10822597B2/en active Active
2019
- 2019-12-20 JP JP2019230887A patent/JP2020058375A/ja active Pending
2020
- 2020-10-16 US US17/072,893 patent/US11746340B2/en active Active
2022
- 2022-07-22 JP JP2022117484A patent/JP7408734B2/ja active Active
2023
- 2023-05-30 US US18/325,714 patent/US20240174994A1/en active Pending

Also Published As

Publication number	Publication date
MX2016009625A (es)	2017-05-01
US20170009216A1 (en)	2017-01-12
RU2683635C2 (ru)	2019-03-29
CN111778228A (zh)	2020-10-16
DK3097189T3 (en)	2018-09-03
ZA201605028B (en)	2020-02-26
JP6940949B2 (ja)	2021-09-29
RU2016131879A3 (ru)	2018-08-16
JP7408734B2 (ja)	2024-01-05
HUE039784T2 (hu)	2019-02-28
US20210163905A1 (en)	2021-06-03
US9926544B2 (en)	2018-03-27
JP2020058375A (ja)	2020-04-16
SG11201606060WA (en)	2016-08-30
KR102166110B1 (ko)	2020-10-16
NZ722253A (en)	2021-11-26
CA2937328C (en)	2022-09-27
US20240174994A1 (en)	2024-05-30
BR112016017041A2 (pt)	2017-10-03
JP2017505128A (ja)	2017-02-16
SA516371532B1 (ar)	2019-02-11
WO2015112017A1 (en)	2015-07-30
US11746340B2 (en)	2023-09-05
EP3097189B1 (en)	2018-07-11
EP3425048A1 (en)	2019-01-09
CN106164262A (zh)	2016-11-23
KR20160117487A (ko)	2016-10-10
BR112016017041B1 (pt)	2023-09-26
IL246898A0 (en)	2016-09-29
CA2937328A1 (en)	2015-07-30
SI3097189T1 (sl)	2018-10-30
US10822597B2 (en)	2020-11-03
US20190024062A1 (en)	2019-01-24
IL246898B (en)	2019-09-26
JP2022160503A (ja)	2022-10-19
ES2684639T3 (es)	2018-10-03
MX369041B (es)	2019-10-25
AU2015209783B2 (en)	2020-10-01
PH12016501441A1 (en)	2016-08-22
AU2015209783A1 (en)	2016-08-04
PL3097189T3 (pl)	2018-11-30
RU2016131879A (ru)	2018-03-01
EP3097189A1 (en)	2016-11-30
CN106164262B (zh)	2020-08-07

Publication	Publication Date	Title
PE20161442A1 (es)	2017-01-12	Proteinas quimericas tipo fosfatasa alcalina
EA201792651A1 (ru)	2018-06-29	Аденовирусные полинуклеотиды и полипептиды
PE20170665A1 (es)	2017-06-10	Anticuerpos anti-tau humanizados
TN2017000085A1 (en)	2018-07-04	Polypeptide having a polyester degrading activity and uses thereof
EA201791426A1 (ru)	2017-11-30	Полипептид и иммуномодуляция
EA201792245A1 (ru)	2018-07-31	Биоконъюгаты и их применения
PE20130041A1 (es)	2013-01-28	Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
ES2721309T3 (es)	2019-07-30	Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
HRP20210734T1 (hr)	2021-06-11	Koštani morfogenetski proteini
HRP20220531T1 (hr)	2022-06-10	Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda
BR112015021269A2 (pt)	2017-10-10	peptídeos e composições para tratamento de dano articular
UA118167C2 (uk)	2018-12-10	Пептид та його застосування
EA201491277A1 (ru)	2014-09-30	Противораковый слитый белок
PE20171336A1 (es)	2017-09-13	Anticuerpos contra tau y sus usos
CO2017008520A2 (es)	2017-11-10	Variantes de polipéptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes, así como procedimientos para la división de toxinas de fusarium
AR120721A2 (es)	2022-03-09	Péptidos y composiciones para el tratamiento de daño articular
EA201691011A1 (ru)	2017-02-28	Последовательность модифицированного эндолизина el188
PE20170955A1 (es)	2017-07-13	Nuevas proteinas inhibidoras de insectos
WO2015198240A3 (en)	2016-03-17	Compositions and methods for long acting proteins
CL2017000200A1 (es)	2017-07-14	Célula huésped mejorada para producir proteinas
AR101555A1 (es)	2016-12-28	ANTICUERPOS DIRIGIDOS AL RECEPTOR IIB DE Fc g Y AL RECEPTOR DE Fc e
EA201691981A1 (ru)	2017-03-31	Улучшенные транспортные молекулы модулярного антигена и их применение
EA201691004A1 (ru)	2017-01-30	Последовательность модифицированного эндолизина kz144
EA201590601A1 (ru)	2015-08-31	Применение pedf-производных полипептидов для лечения остеоартрита
PH12019501064A1 (en)	2019-08-19	Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION